Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Siemens Healthineers expands into cancer care with $16.4 billion deal for Varian

Stock MarketsAug 02, 2020 09:45AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. A staffer works on a magnetic resonance imaging machine at a production line of Siemens Healthineers in Shenzhen

By Jörn Poltz and Douglas Busvine

MUNICH/BERLIN (Reuters) - German health group Siemens Healthineers (DE:SHLG) said on Sunday it was buying Varian Medical Systems Inc (N:VAR) of the United States for $16.4 billion in a deal that seeks to create the global leader in cancer care solutions.

The deal is the first major growth move by Healthineers since it was spun off and floated in 2018 by Siemens (DE:SIEGn), which is undertaking a broader shakeup of its conglomerate structure to create room for its business units to do their own deals.

Siemens, which will retain control over Healthineers, will provide bridge financing for the deal that will be partly refinanced by a rights issue by the medical technology unit later this year.

Under the agreed transaction, Healthineers will acquire all shares in Varian for $177.50 each in cash, representing a 24% premium to the U.S. company's closing price on Friday and 42% above its 30-day weighted average.

"With this takeover, we are significantly strengthening our position - in addition to cardiology and neurology - in the field of oncology," Chief Financial Officer Jochen Schmitz told Reuters in an interview.

CEO Bernd Montag rejected suggestions that Healthineers had overpaid for Varian. "This is an icon in our industry," he told reporters on a conference call. "If you put it into perspective we achieved a sensible price."

Through the deal to buy Varian, Healthineers acquires the leader in radiation therapy with a market share of over 50%.

Healthineers highlighted a long-term rise in the incidence of cancer - from 14 million cases worldwide in 2010 to a forecast 25 million in 2030.

That translates into an addressable market of $20 billion that is forecast to grow at an annual rate of between 6% and 10%, the company said in a presentation on the deal.

The transaction, first reported by Bloomberg, is subject to approval by Varian shareholders and regulators. It is expected to close in the first half of 2021 and be accretive to Siemens Healthineers' adjusted basic earnings per share within 12 months of that.

"With Siemens Healthineers, we will transform care for a greater number of patients worldwide, as well as broaden opportunities for our employees as part of a larger and more global organization," Varian President and Chief Executive Officer Dow Wilson said.

BALANCE SHEET SUPPORT

Conglomerate Siemens is effectively putting its balance sheet to work to fund the deal, providing a bridging loan of 15.2 billion euros ($17.9 billion) to Healthineers.

The medical technology unit aims to replace 50% of that through a rights issue this year, subject to market conditions.

Siemens said in a statement that it expressly welcomed the deal and would raise the money for the bridging loan by issuing bonds. It will not participate in the rights issue, meaning its stake in Healthineers will be diluted to about 72% from 85%.

Siemens aims to maintain its A+ debt ratings, which put it firmly in investment grade.

Healthineers also pre-released fiscal third quarter results instead of on Monday due to the acquisition announcement. They showed its revenue declined 6.9% year-on-year on a comparable basis to 3.3 billion euros due to the impact of the coronavirus pandemic.

Its adjusted operating margin was 13.9%, down 1.2 percentage points from the same period a year earlier, while adjusted basic earnings per share fell 21% to 30 euro cents.

The company said it expects revenue to be flat in fiscal 2020 while adjusted basic earnings per share are seen at between 1.54 and 1.62 euros, compared to 1.70 euros last year, assuming the business environment does not deteriorate further.

Siemens Healthineers expands into cancer care with $16.4 billion deal for Varian
 

Related Articles

Wall Street ends sharply lower in broad sell-off
Wall Street ends sharply lower in broad sell-off By Reuters - Sep 20, 2021 33

By Caroline Valetkevitch NEW YORK (Reuters) - Wall Street plunged on Monday as fear of contagion from a potential collapse of China's Evergrande prompted a broad sell-off and sent...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Cody Parsons
Cody Parsons Aug 02, 2020 4:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
all in
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email